Your browser is out-of-date!

Update your browser to view this website correctly.

Disclaimer
To continue, please select your country of domicile and investor type. Depending on your domicile and the investor type that you select, you will have full or restricted access to the information due to legal reasons.

Retail clients: according to Art. 4 Abs. 2 FinSA

Professional/Institutional investors: according to Art. 4 paragraph 3-5 and Art. 5 paragraph 1 and 3-4 FinSA and Art. 10 paragraph 3 and 3ter CISA in conjunction with Art. 6a CISO

Important

Principles 

By using the website www.bellevue.ch, you confirm that you have read, understood and accepted the general information provided by the Bellevue Group AG as well as these legal provisions. These may be subject to change and the use of the site may be restricted or terminated at any time without prior notice.

No recommendation and/or offer for subscription (or for purchase) and/or redemption (or for sale)

The information, products, data, services, tools and documents contained or described on this site ("website content") are for information purposes only and constitute neither an advertisement or recommendation nor an offer or solicitation (to buy) or redemption (sell) investment instruments, to effect any transaction or to enter into any legal relations.

The financial products mentioned on this site are not suitable for all investors. The information contained on this site does not constitute a financial, legal, fiscal or any other recommendation. Investment or other decisions should not be made solely on the basis of this document. In particular, you should not enter into any investment before you have read the corresponding fund agreement or legal prospectus, the annual and semi-annual reports, the articles of association (as far as they are applicable), as well as all other documents, as required in accordance with local legislation or the regulations applied in the legal jurisdictions or countries in which the corresponding investment fund has been licensed or approved for public offer or sale to the public.rlich sind.

The financial products mentioned on this site are not suitable for all investors. The information contained on this site does not constitute a financial, legal, fiscal or any other recommendation. Investment or other decisions should not be made solely on the basis of this document. In particular, you should not enter into any investment before you have read the corresponding fund agreement or legal prospectus, the annual and semi-annual reports, the articles of association (as far as they are applicable), as well as all other documents, as required in accordance with local legislation or the regulations applied in the legal jurisdictions or countries in which the corresponding investment fund has been licensed or approved for public offer or sale to the public.

In order to determine whether the investment in shares of a certain investment fund meets your specific requirements and matches your envisaged risks, we recommend that you contact an independent financial adviser. Furthermore, we recommend that you consult an independent tax adviser in order to obtain information on the tax regulations relating to a specific investment in your legal jurisdiction and with regard to your personal circumstances. In particular tax treatment depends on individual circumstances and may be subject to change.

As the funds are recognised (ie. registered) but not authorised in the UK, the UK Financial Services Authority's financial services compensation scheme does not apply to investments in the fund but the Financial Services Authority regulated firm approving this document for the purposes of UK regulation has taken reasonable steps to satisfy itself that Bellevue will deal in an honest and reliable way and is so satisfied.

Performance

Past performance is not an indication or guarantee of the future performance of the investment. The value of investments may be subject to fluctuations and, under certain circumstances, investors may not get back the full amount invested. The performance data are calculated without taking account of commissions and costs that result from subscriptions and redemptions and commissions and costs have a negative impact on performance. Changes in foreign-exchange rates may also cause the value of investments to go up or down.

Target group of the sites 

The sites are intended exclusively for use by legal entities and natural persons having their registered office or residing in countries in which the investment funds or the related subfunds or share classes of the Bellevue Group have been properly licensed or approved for public offer or sale in accordance with the applicable local legislation. The funds are currently registered for public distribution offer in the following countries: Luxembourg, Switzerland, Germany, Austria and Spain. In all other countries, the funds may, if any, via "Private Placement" according to the local applicable laws.

It is explicitly stated, that alternative fund products are not allowed for public distribution in any country and that they may only and exclusively be solicited to institutional and qualified private investors according to the applicable local laws of each country.

The information and services provided on the sites are not intended for offer to or use by legal entities or natural persons in legal jurisdictions or countries in which the offer or use thereof would violate local legislation or legal provisions, or in which business units forming part of Bellevue Group would be subject to registration requirements in such jurisdictions or countries. Legal entities or natural persons to which such prohibitions apply must not access or use these sites.

The Bellevue funds have NOT been licensed for public offer or sale to the public in the United States in accordance with the US Investment Company Act of 1940 or the US Securities Act of 1933, or in Canada, Japan, Taiwan, Malaysia, Hong Kong or Israel in accordance with the laws in force in those countries. Therefore, particular importance is attached to ensuring that these sites are not intended for legal entities or natural persons, who have their registered office or who reside in such countries, their territories or dependencies or who, on account of their citizenship or similar status, are subject to the law of one of these countries.

Fund documents Luxembourg Fund

Bellevue SICAV: The Bellevue Funds (Lux) SICAV is admitted for public offering and distribution in Switzerland . Representative agent in Switzerland   Waystone Fund Services (Switzerland) SA, Avenue Villamont 17, CH-1005 Lausanne and paying agent in Switzerland: DZ PRIVATBANK (Schweiz) AG Münsterhof 12, PO Box, CH-8022 Zürich . The Bellevue Funds (Lux) SICAV is admitted for public distribution in Austria . Paying and information agent : Erste Bank der oesterreichischen Sparkassen AG, Graben 21 , A - 1010 Vienna . The Bellevue Funds (Lux) SICAV is admitted for public distribution in Germany . Paying and information agent : Bank Julius Bär Europe AG, An der Welle 1 , P . O . Box, D - 60062 Frankfurt a . M . The Bellevue Funds (Lux) SICAV is registered with the CNMV under the number 938 . Prospectus, Key Investor Information Document (“KIID”), the articles of association as well as the annual and semi - annual reports of the Bellevue Funds under Luxembourg law are available free of charge from the above mentioned representative, paying, facilities and information agents as well as from Bellevue Asset Management AG, Seestrasse 16 , CH - 8700 Kusnacht. 

StarCapital: You can obtain the sales prospectus, the annual reports and the german key investor information documents free of charge from StarCapital AG, and also from banks and financial advisers. Paying agent in Switzerland is DZ PRIVATBANK (Schweiz) AG, Münsterhof 12, PO Box, CH-8022 Zurich. The swiss agent is IPConcept (Schweiz) AG, In Gassen 6, PO Box, CH-8022 Zurich. In Switzerland you can obtain sales prospectus, the annual reports and the german key investor information documents free of charge from the agent and also from the paying agent. 

Fund documents Bellevue Entrepreneur Switzerland

Prospectus, Key Investor Information Document („KIID“), fund contract as well as the annual and semi - annual reports of the Bellevue Fund under Swiss law are available free of charge from: Switzerland : PMG Fonds Management AG, Sihlstrasse 95 , CH - 8001 Zürich or Bellevue Asset Management AG, Seestrasse 16, CH - 8700 Kusnacht. 

Fund documents Bellevue Funds and Bellevue Healthcare Strategy

Prospectus, Key Investor Information Document („KIID“), fund contract as well as the annual and semi - annual reports of the Bellevue Medtech and Services fund established under Swiss law in the category "Other Funds for Traditional Investments" are available free of charge from : Switzerland : Swisscanto Fondsleitung AG, Bahnhofstrasse 9 , CH - 8001 Zürich or Bellevue Asset Management AG, Seestrasse 16 , CH - 8700 Kusnacht

Fund documents StarCapital Equity Value plus, StarCapital Multi Income, StarCapital Strategy 1 and StarCapital Dynamic Bonds.

Prospectus, the key investor information document (KIID), the management regulations and the semi-annual and annual report are available free of charge in German from StarCapital AG, your advisor or intermediary, the paying agents, the relevant custodian bank or from the management company IPConcept (Luxembourg) S.A. (société anonyme), 4, rue Thomas Edison, L-1445 Luxembourg, Luxembourg, https://www.ipconcept.com. For information on opportunities and risks as well as tax information, please refer to the current detailed sales prospectus. Further information on investor rights can be found on the Management Company's website (https://www.ipconcept.com). The management company may decide to cancel the arrangements it has made for the distribution of the units of its collective investment undertakings in accordance with Article 93a of Directive 2009/65/EC and Article 32a of Directive 2011/61/EU.

Fund documents Bellevue Option Premium fund

Prospectus, the key investor information document (KIID), the management regulations and the semi-annual and annual reports are available free of charge in German from StarCapital AG, your advisor or intermediary, the paying agents, the responsible depositary (UBS Europe SE, Bockenheimer Landstrasse 2-4, D-60306 Frankfurt am Main) or from the management company Universal-Investment-Gesellschaft mbH, Theodor-Heuss-Allee 70, D-60486 Frankfurt am Main, https://www.universal-investment.com. For information on opportunities and risks as well as tax information, please refer to the current detailed sales prospectus. Further information on investor rights can be found on the Management Company's website (https://www.universal-investment.com). The management company may decide to cancel the arrangements it has made for the distribution of the units of its collective investment undertakings in accordance with Article 93a of Directive 2009/65/EC and Article 32a of Directive 2011/61/EU.

 Fund documents StarCapital Premium Bonds plus  

Prospectus, the key investor information document (KIID), the management regulations and the semi-annual and annual reports. These can be obtained free of charge in German from StarCapital AG, your advisor or intermediary, the paying agents, the responsible depositary (UBS Europe SE, Bockenheimer Landstrasse 2-4, D-60306 Frankfurt am Main) or from the management company Donner & Reuschel AG, Ballindamm 27, 20095 Hamburg, https://www.donner-reuschel.de. For information on opportunities and risks as well as tax information, please refer to the current detailed sales prospectus. Further information on investor rights can be found on the Management Company's website (https://www.universal-investment.com). The management company may decide to cancel the arrangements it has made for the distribution of the units of its collective investment undertakings in accordance with Article 93a of Directive 2009/65/EC and Article 32a of Directive 2011/61/EU.

Data protection

By accessing this website you state that you agree with the data protection statement. If you do not agree with this statement you should refrain from accessing any further pages of this website. This statement may be updated at any time. We therefore recommend that you check this statement regularly.

Confirmation

By clicking on "Accept", you confirm that you agree to the legal provisions. Alternatively, you can select "I don't accept" if you wish to leave the website.

A new generation of glucose sensors and insulin pumps heralds a big improvement in the quality of diabetes therapy.

Digital diabetes management – a success story for patients and for investors

A new generation of glucose sensors and insulin pumps heralds a big improvement in the quality of diabetes therapy.
07.10.2022 - Marcel Fritsch

The numbers speak for themselves. According to the International Diabetes Federation (IDF), 530 million people worldwide, or one in ten adults, had diabetes in 2021. Compared to the diabetes statistics from the year 2000, the number of people with diabetes tripled over this period. By 2045, the number of diabetes patients is expected to increase to more than 780 million, which would correspond to a five-fold increase from the millennium year. 10% of all patients have type 1 diabetes, which is usually diagnosed during childhood or adolescence. Type 1 diabetes is an autoimmune disease that results from the destruction of pancreatic beta cells, which regulate blood glucose levels, by the body's own immune system. Type 2 diabetes, which is usually diagnosed later in life, is caused by obesity, unhealthy diets, and sedentary lifestyles. The pancreas produces insulin, but either it's not enough or the body cannot use the insulin effectively (insulin resistance).

Diabetes treatment costs spiraling out of control
Diabetes is taking an increasingly heavy financial toll on healthcare systems. According to the IDF, this metabolic disorder results in annual healthcare spending of USD 970 bn, of which USD 420 bn is spent in North America. Treatment-related costs have more than quadrupled over the past 15 years, which is likely primarily attributable to the various serious complications that are associated with diabetes, such as strokes, heart attacks, vision loss and blindness, and renal failure. In order to effectively manage diabetes and the health problems it can cause, a patient’s blood glucose levels must be kept within a target range of 70 to 180 milligrams of blood glucose per deciliter of blood as much as possible. The blood glucose levels of a healthy person without diabetes will be in range about 90% of the time.

Thanks to new digital technologies, a diabetes patient’s time in range can be increased to 70-80% over a 24-hour period, depending on the patient. This is achieved by combining "real-time" CGM systems with automatic insulin delivery (AID) systems. In the CGM systems, interstitial glucose levels in subcutaneous tissue are continuously measured at regular intervals every few minutes. These glucose readings are transmitted via Bluetooth to the AID system and to the patient's smartphone.

Algorithms integrated into the AID system analyze glucose patterns and automatically decide whether insulin should be administered and, if so, how much. A smartphone app will display graphical summaries of glucose and insulin readings and warn patients if current or predicted glucose levels are excessively high or low. Patients can use the app to administer bolus insulin before meals too. All patient data is automatically uploaded to the cloud, where it can be accessed by healthcare professionals, who analyze the effectiveness of the insulin therapy and make adjustments if necessary. In addition to the patient, other persons such as family members can also view the data using an app.

Companies in the spotlight
From a patient and investor standpoint, Abbott’s FreeStyle Libre 3 and Dexcom’s G6 are the leading CGM systems in the market today. Abbott’s product has the largest patient base, more than 4 million and counting, and it also has price leadership. The main disadvantage of the FreeStyle Libre 3 is that it has not yet been approved by the FDA for integration with automated insulin delivery systems. Dexcom’s G6, conversely, was authorized in the US as a fully interoperable CGM that can communicate with AID systems, which gives Dexcom quality leadership. Furthermore, it has already received European approval for Dexcom G7, a successor product that features several improvements over the G6. The Dexcom G7 boasts the most advanced technology of all CGM systems in the market today based on the accuracy of glucose readings (8.2%) and sensor warmup time (only 30 minutes). The technology behind Medtronic’s Guardian 4 and the Eversense E3 from Senseonics, both of which have been approved in Europe, is not as advanced.

As for automatic insulin delivery systems, two products share market leadership and have unique quality profiles. Tandem Diabetes’ t:slim X2 insulin pump featuring Control-IQ technology and Insulet’s Omnipod 5 are both authorized in the US, are interoperable with Dexcom’s G6, and can deliver both basal insulin and pre-meal bolus insulin via a smartphone app. Medtronic’s MiniMed 780G insulin pump has only been authorized in Europe so far and it is interoperable with the Guardian 4 sensor, which is not as advanced as other CGM systems. Like the t:slim X2, the MiniMed 780G uses thin plastic tubing to deliver insulin from the pump to the body; it has a useful life of three to four years. The tubeless, waterproof Omnipod 5 is a very small patch-like pump that is worn directly on the body. It is authorized for patients two years and older and must be replaced every three days. The Omnipod 5 is available for prescription through pharmacy channels and is considered to be an ideal entry-level AID system.

Huge market potential for innovation leaders and for investors
We expect global sales of CGM systems to triple to around USD 12 bn in the 2019-2025 period. Sales of AID systems are forecast to nearly double to USD 5 bn over that same period. Growth will accelerate during the next few years once the FreeStyle Libre 3 is authorized to be interoperable with an AID system. Furthermore, Tandem Diabetes is expected to be granted marketing authorization for Mobi:Tubeless in 2024. This is a reusable patch pump that features an adhesive patch with a built-in infusion cannula or needle instead of an infusion set.

Within the medtech sector, digital diabetes management is viewed as one of the most disruptive technologies with the greatest growth potential in the years to come. In both of our specialty investment funds, the Bellevue Medtech & Services Fund and the Bellevue Digital Health Fund, 17% of total portfolio assets are currently allocated to companies that generate some or all of their sales in the diabetes market. These two funds have different risk profiles. The Bellevue Medtech & Services Fund is predominately invested in large-cap stocks (92% weighting), and digital health companies represent 35% of its portfolio assets. The Bellevue Digital Health Fund has a much higher allocation to small- and mid-cap equities (57%). Its investments include Dexcom, Insulet and Tandem Diabetes, companies whose sales growth is forecast to increase sharply in the wake of product innovation.

These investment strategies might interest you